logo image
search icon
Global Adalimumab Biosimilar Market

Adalimumab Biosimilar Market Size, Share & Trends Analysis Report By Product (Amjevita, Cyltezo, Hadlima, Yusimry, Hulio, Hymiroz, Abrilada, Yuflyma, Exemptia, Adalirel, Cipleumab and other pipeline products), By Application, By Distribution Channel, By Region, And By Segment Forecasts, 2023-2031

Report ID : 1058 | Published : 2023-04-19 | Pages: 180 | Format: PDF/EXCEL

The Adalimumab Biosimilar Market Size is valued at 613.28 Million in 2022 and is predicted to reach 3954.75 Million by the year 2031 at a 23.2 % CAGR during the forecast period for 2023-2031.

Adalimumab Biosimilar Market

Adalimumab is a human monoclonal antibody that inhibits tumor necrosis factor (TNF), which is a soluble inflammatory cytokine, to treat autoimmune disorders. Adalimumab binds to TNF-alpha (TNF-), blocking it from activating TNF receptors, which are responsible for autoimmune disorders' inflammatory responses. Adalimumab treats rheumatoid, juvenile idiopathic, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. These can be treated with several biosimilars that have been approved by the EMA (European Medicines Agency) and the Food and Drug Administration (FDA) of the United States (U.S.). About 240 biosimilar candidates are being made for all diseases. The Adalimumab Biosimilar market keeps growing due to more strategic partnerships and acquisitions. Biosimilars also bring down the cost of treatment, which helps patients get the care they need.

It was first discovered by the "phage display" technique which was named 'D2E7'. Furthermore, it experienced the various manufacturing process at BASF Bioresearch Corporation and developed by BASF Knoll. In December 2000, Abbott announced the acquisition of BASF Bioresearch Corporation.

Abbott Laboratories spun off its pharmaceutical division, AbbVie Inc., in January 2013. AbbVie sold Adalimumab under the brand name Humira. The FDA and European Medicines Agency authorised it in 2008 and 2003, respectively. Humira's patent expired in June 2017 in Europe and November 2017 in the US. Biosimilar adalimumab products are being developed by numerous pharmaceutical companies because it is the world's best-selling medicine.

The market for biosimilar adalimumab is anticipated to expand at a high rate throughout the forecast period. Adalimumab is one of the top-selling medications in the world. In addition, the entry of adalimumab biosimilar competitors into the market is anticipated to stimulate the expansion of the worldwide adalimumab biosimilar market. The market for biosimilar Adalimumab continues to expand due to additional strategic collaborations and acquisitions. Biosimilars also reduce the cost of treatment, enabling patients to receive the care they require. During the projected period, the market for biosimilar adalimumab will be propelled by the rising demand for biosimilar pharmaceuticals and the rising demand for cost-effective therapy in low- and middle-income nations.

However, the complex regulatory process for the licencing of biosimilars is the key factor impeding the expansion of the adalimumab biosimilars market. In addition, the measures employed by patent holder businesses to combat biosimilar competition hinder the expansion of the adalimumab biosimilar industry. For example, Abbvie filed a complaint against Boehringer Ingelheim about a biosimilar Humira product.

Market Segmentation

The Adalimuman biosimilar market is segmented into three main segments. First is Product then application and distribution channels. The Product segment has Amjevita, Cyltezo, Hadlima, Yusimry, Hulio, Hymiroz, Abrilada, Exemptia, Adalirel, Cipleumab.  Based on application, the global adalimumab biosimilar market is segmented into rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis, ulcerative colitis, and psoriasis. The rheumatoid arthritis application segment is expected to grow at a higher pace during the forecast period owing to the increasing incidence and prevalence rate of disease across the globe. Based on distribution channels, the global adalimumab biosimilar market is segmented as hospital pharmacies, online pharmacies and other direct distribution channels.

Competitive Landscape

Some Major Key Players In The Adalimumab Biosimilar Market:

  • Amgen,
  • Pfizer,
  • Sandoz International GmbH,
  • Celltrion Healthcare Co., Ltd.,
  • Fresenius Kabi,
  • Kyowa Hakko Kirin,
  • G. Life Sciences,
  • Mochida Pharmaceutical,
  • Momenta Pharmaceuticals.
  • BIOCND
  • Baxalta (Shire)
  • Organon
  • Teva
  • Bio-Thera Solutions
  • Biocad
  • Boehringer Ingelheim
  • CinnaGen
  • Coherus Biosciences
  • Hetero Drugs
  • Hisun Pharmaceuticals
  • Innovent Biologics
  • Neuclone
  • Outlook Therapeutics
  • Prestige Biopharma
  • Reliance Life Sciences
  • Samsung Bioepis
  • Shanghai Henlius Biotech
  • Shanghai Junshi Biosciences
  • Torrent Pharmaceuticals
  • Zydus Cadila
  • Amneal Pharmaceuticals, Inc.
  • Hospira Inc.
  • Mylan Pharmaceuticals Inc.
  • Kashiv BioSciences, LLC

Adalimumab Biosimilar Market Report Scope

Report Attribute

Specifications

Market Size Value In 2022

USD 613.28 Million

Revenue Forecast In 2031

USD 3954.75 Million

Growth Rate CAGR

CAGR of 23.2 % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Million and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Product, Application, Distribution Channel

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Competitive Landscape

Amgen, Pfizer, Celltrion Healthcare Co., Ltd., Sandoz International GmbH, LG Life Sciences, Mochida Pharmaceutical, Fresenius Kabi, Kyowa Hakko Kirin, and Momenta Pharmaceuticals, BIOCND, Baxalta (Shire), Organon, Teva, Bio-Thera Solutions, Biocad, Boehringer Ingelheim, CinnaGen, Coherus Biosciences, Hetero Drugs, Hisun Pharmaceuticals, Innovent Biologics, Neuclone, Outlook Therapeutics, Prestige Biopharma,Reliance Life Sciences, Samsung Bioepis, Shanghai Henlius Biotech, Shanghai Junshi Biosciences, Torrent Pharmaceuticals, Zydus Cadila, Kashiv BioSciences, LLC, Hospira Inc., Mylan Pharmaceuticals Inc., Amneal Pharmaceuticals, Inc., and others.

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Adalimumab Biosimilar Market Snapshot

Chapter 4. Global Adalimumab Biosimilar Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Clinical Trial/Pipeline Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Product, Estimates & Trend Analysis

5.1. By Product, & Market Share, 2019 & 2031

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Product:

5.2.1. Amjevita

5.2.2. Cyltezo

5.2.3. Hadlima

5.2.4. Yusimry

5.2.5. Hulio

5.2.6. Hymiroz

5.2.7. Abrilada

5.2.8. Yuflyma

5.2.9. Exemptia

5.2.10. Adalirel

5.2.11. Cipleumab

5.2.12. Other pipeline products

Market Segmentation 2: By Application Estimates & Trend Analysis

5.3. By Application & Market Share, 2019 & 2031

5.4. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Application:

5.4.1. Rheumatoid Arthritis

5.4.2. Juvenile Idiopathic Arthritis

5.4.3. Psoriatic Arthritis

5.4.4. Crohn’s Disease

5.4.5. Ankylosing Spondylitis

5.4.6. Ulcerative Colitis

5.4.7. Psoriasis

Market Segmentation 3: By Distribution Channel Estimates & Trend Analysis

5.5. By Distribution Channel & Market Share, 2019 & 2031

5.6. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Distribution Channel:

5.6.1. Hospital Pharmacy

5.6.2. Online Pharmacy

5.6.3. Retail Pharmacy

5.6.4. Other Direct Distribution Channels

Adalimumab Biosimilar Market Segmentation 5: Regional Estimates & Trend Analysis

5.7. North America

5.7.1. North America Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Product, 2023-2031

5.7.2. North America Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Application, 2023-2031

5.7.3. North America Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2023-2031

5.7.4. North America Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts by country, 2023-2031

5.8. Europe

5.8.1. Europe Adalimumab Biosimilar Market revenue (US$ Million) By Product, 2023-2031

5.8.2. Europe Adalimumab Biosimilar Market revenue (US$ Million) By Application, 2023-2031

5.8.3. Europe Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2023-2031

5.8.4. Europe Adalimumab Biosimilar Market revenue (US$ Million) by country, 2023-2031

5.9. Asia Pacific

5.9.1. Asia Pacific Adalimumab Biosimilar Market revenue (US$ Million) By Product, 2023-2031

5.9.2. Asia Pacific Adalimumab Biosimilar Market revenue (US$ Million) By Application, 2023-2031

5.9.3. Asia Pacific Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2023-2031

5.9.4. Asia Pacific Adalimumab Biosimilar Market revenue (US$ Million) by country, 2023-2031

5.10. Latin America

5.10.1. Latin America Adalimumab Biosimilar Market revenue (US$ Million) By Product, (US$ Million) 2023-2031

5.10.2. Latin America Adalimumab Biosimilar Market revenue (US$ Million) By Application, (US$ Million) 2023-2031

5.10.3. Latin America Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2023-2031

5.10.4. Latin America Adalimumab Biosimilar Market revenue (US$ Million) by country, 2023-2031

5.11. Middle East & Africa

5.11.1. Middle East & Africa Adalimumab Biosimilar Market revenue (US$ Million) By Product, (US$ Million) 2023-2031

5.11.2. Middle East & Africa Adalimumab Biosimilar Market revenue (US$ Million) By Application, (US$ Million) 2023-2031

5.11.3. Middle East & Africa Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2023-2031

5.11.4. Middle East & Africa Adalimumab Biosimilar Market revenue (US$ Million) by country, 2023-2031

Chapter 6. Competitive Landscape

6.1. Major Mergers and Acquisitions/Strategic Alliances

6.2. Company Profiles

  • Amgen,
  • Pfizer,
  • Sandoz International GmbH,
  • Celltrion Healthcare Co., Ltd.,
  • Fresenius Kabi,
  • Kyowa Hakko Kirin,
  • G. Life Sciences,
  • Mochida Pharmaceutical,
  • Momenta Pharmaceuticals.
  • BIOCND
  • Baxalta (Shire)
  • Organon
  • Teva
  • Bio-Thera Solutions
  • Biocad
  • Boehringer Ingelheim
  • CinnaGen
  • Coherus Biosciences
  • Hetero Drugs
  • Hisun Pharmaceuticals
  • Innovent Biologics
  • Neuclone
  • Outlook Therapeutics
  • Prestige Biopharma
  • Reliance Life Sciences
  • Samsung Bioepis
  • Shanghai Henlius Biotech
  • Shanghai Junshi Biosciences
  • Torrent Pharmaceuticals
  • Zydus Cadila
  • Amneal Pharmaceuticals, Inc.
  • Hospira Inc.
  • Mylan Pharmaceuticals Inc.
  • Kashiv BioSciences, LLC

Global Adalimumab Biosimilar Market Segmentation

Global Adalimumab Biosimilar Market, by Product, 2023-2031 (Value US$ Mn)

  • Amjevita
  • Cyltezo
  • Hadlima
  • Yusimry
  • Hulio
  • Hymiroz
  • Abrilada
  • Yuflyma
  • Exemptia
  • Adalirel
  • Cipleumab
  • Other pipeline products

Adalimumab Biosimilar Market

Global Adalimumab Biosimilar Market, by Application, 2023-2031 (Value US$ Mn)

  • Rheumatoid Arthritis
  • Juvenile Idiopathic Arthritis
  • Psoriatic Arthritis
  • Crohn’s Disease
  • Ankylosing Spondylitis
  • Ulcerative Colitis
  • Psoriasis

Global Adalimumab Biosimilar Market, by Distribution Channel, 2023-2031 (Value US$ Mn)

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Other Direct Distribution Channels

Global Adalimumab Biosimilar Market, by Region, 2023-2031 (Value US$ Mn)

  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • India
    • China
    • Japan
    • South Korea
    • Australia & New Zealand
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

 

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Adalimumab Biosimilar Market Size?

The Adalimumab Biosimilar Market is expected to grow at a 23.2 % CAGR during the forecast period for 2023-2031.

Amgen, Pfizer, Celltrion Healthcare Co., Ltd., Sandoz International GmbH, LG Life Sciences, Mochida Pharmaceutical, Fresenius Kabi, Kyowa Hakko Kirin,

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4500
$7700
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach